Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

  • Regeneron Pharmaceuticals
  • Rewriting Life

    Genes of human “mutants” point to a new superpower

    DNA search finds people resistant to liver disease. Can we mimic the effect with a drug?

    The search for mutations that conjure medical superpowers has turned up people who are resistant to liver disease, even if they drink like crazy.

    Big-time biotech company Regeneron Pharmaceuticals says it found people with a gene mutation that seems to leave them mostly immune to “fatty liver” disease, which is widespread in the US as a result of both alcoholism and overeating.

    Now, the company says, it will partner with gene-silencing specialist Alnylam Pharmaceuticals to create medicines that mimic the effect.

    Regeneron runs one of the world’s largest gene-sequencing operations in partnership with the Geisinger Health System, operator of a large hospital network.

    It has the DNA code and the medical records of thousands of volunteers.

    That allows the company to search for people unusually resistant to certain diseases and then determine if there’s an explanation in their DNA (see “The search for exceptional genomes”).

    Sign up for The Download
    Your daily dose of what's up in emerging technology

    By signing up you agree to receive email newsletters and notifications from MIT Technology Review. You can change your preferences at any time. View our Privacy Policy for more detail.

    The search for genetic superpowers can lead quickly to new drugs, such as a powerful cholesterol-lowering medicine already being sold by Regeneron.

    This time, Regeneron scoured the DNA, blood levels, and electronic records of 46,544 volunteers to look for links to liver damage.

    They zeroed in on a gene called HSD17B13. They found that folks who lack a working copy of this gene had a 73 percent lower chance of cirrhosis due to drinking, and half as big a chance of other types of cirrhosis.

    How the protective effect works isn’t entirely clear. But the two biotech companies say they will now try to create a drug to treat fatty-liver disease.

    About a quarter of Americans suffer from the condition, according to a report published by the Regeneron scientists in the New England Journal of Medicine on March 21.

    Fatty liver is chronic and not always dangerous. The biotech companies say they are looking to treat a specific type called nonalcoholic steatohepatitis, or NASH, which is more likely to lead to liver failure.

    The liver problem is linked to being overweight, so losing weight can slow it down. For those who can’t shed the pounds, Regeneron may eventually have a superpower in a vial.

    Cut off? Read unlimited articles today.

    Become an Insider
    Already an Insider? Log in.
    More from Rewriting Life

    Reprogramming our bodies to make us healthier.

    Want more award-winning journalism? Subscribe to Insider Plus.
    • Insider Plus {! insider.prices.plus !}*

      {! insider.display.menuOptionsLabel !}

      Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

      See details+

      Print + Digital Magazine (6 bi-monthly issues)

      Unlimited online access including all articles, multimedia, and more

      The Download newsletter with top tech stories delivered daily to your inbox

      Technology Review PDF magazine archive, including articles, images, and covers dating back to 1899

      10% Discount to MIT Technology Review events and MIT Press

      Ad-free website experience

    /3
    You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.